NCT00745225View on ClinicalTrials.gov

Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
End-stage Renal Disease
Interventions
DRUG

Pioglitazone

pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks

DRUG

placebo comparator

1 capsule daily, 96 weeks.

Trial Locations (1)

0000

Queen Mary Hospital, Tung Wah Hospital, Hong Kong

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

The University of Hong Kong

OTHER

NCT00745225 - Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients | Biotech Hunter | Biotech Hunter